Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor targeting a specific Gag cleavage site between capsid p24 and spacer peptide 1 of HIV-1. Study 205891 (previously AI468038) investigated the efficacy, safety, and dose response of GSK3532795 in treatment-naive, HIV-1-infected participants. Study 205891 (NCT02415595) was a Phase IIb, randomized, active-controlled, double-blind, international trial. Participants were randomized 1:1:1:1 to one of three GSK3532795 arms at doses 60 mg, 120 mg or 180 mg once daily (QD), or to efavirenz (EFV) at 600 mg QD, each in combination with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) (300/200 mg QD). Primary endpoint was proportion of participants with plasma HIV-1 RNA <40 copies/mL at Week 24. Between May 2015 and May 2016, 206 participants received treatment. At Week 24, 76–83% participants receiving GSK3532795 and 77% receiving EFV achieved HIV-1 RNA <40 copies/mL. Fifteen participants receiving GSK3532795 and one receiving EFV met resistance testing criteria; 10/15 receiving GSK3532795 had emergent substitutions at reverse transcriptase positions M184, and one at position K65, while the participant receiving EFV did not have any nucleoside reverse transcriptase inhibitor (NRTI)/non-NRTI mutations. EFV, relative to GSK3532795, had more serious adverse events (9% versus 5%) and adverse events leading to discontinuation (17% versus 5%). However, 3–4-fold higher rates of gastrointestinal adverse events were observed with GSK3532795 relative to EFV. GSK3532795 combined with TDF/FTC is efficacious with 24 weeks of therapy. However, GSK3532795 showed a higher rate of gastrointestinal intolerability and treatment-emergent resistance to the NRTI backbone relative to EFV.

          Trial registration: ClinicalTrials.gov NCT02415595.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          Maturation inhibitors: a new therapeutic class targets the virus structure.

          The current standard of care for HIV/AIDS in the developed world is HAART therapy, usually a combination of two reverse transcriptase inhibitors and a protease inhibitor. Despite the success of this regimen, there is a continuing need for new drug options to overcome problems with tolerability and the emergence of viral resistance. In this review we discuss the discovery of a potential new class of antiretroviral therapeutics, known as maturation inhibitors, and the development of the first-in-class compound, bevirimat. Bevirimat is distinguished from the currently available antiretrovirals by its unique target and mode of action. While the specific interactions responsible for activity have yet to be fully characterized, it is clear that the target for bevirimat is the Gag polyprotein precursor, the main structural protein responsible for assembly and budding of virion particles. As basic research continues on the precise mechanism of action of bevirimat, clinical development is progressing, with demonstration of both safety and efficacy in early-stage trials. These encouraging results, coupled with the discovery and development of future generations of maturation inhibitors, suggest that maturation inhibitors may be added to the growing set of tools available to control HIV/AIDS.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.

            Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.
              Bookmark

              Author and article information

              Contributors
              Role: InvestigationRole: Resources
              Role: InvestigationRole: Resources
              Role: InvestigationRole: Resources
              Role: InvestigationRole: Resources
              Role: Formal analysis
              Role: Formal analysis
              Role: Formal analysis
              Role: Formal analysis
              Role: Formal analysis
              Role: Formal analysis
              Role: Formal analysis
              Role: Formal analysisRole: Project administration
              Role: Formal analysis
              Role: Editor
              Journal
              PLoS One
              PLoS ONE
              plos
              plosone
              PLoS ONE
              Public Library of Science (San Francisco, CA USA )
              1932-6203
              23 October 2018
              2018
              : 13
              : 10
              : e0205368
              Affiliations
              [1 ] Clinical Research Puerto Rico Inc., San Juan, Puerto Rico
              [2 ] Med IV, Hospital of the University of Munich, Munich, Germany
              [3 ] Hôpital St Louis, Paris, France
              [4 ] Josha Research, Bloemfontein, South Africa
              [5 ] ViiV Healthcare, Branford, Connecticut, United States of America
              [6 ] Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
              [7 ] ViiV Healthcare, Research Triangle Park, North Carolina, United States of America
              [8 ] GlaxoSmithKline, Upper Merion, Pennsylvania, United States of America
              Azienda Ospedaliera Universitaria di Perugia, ITALY
              Author notes

              Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: IBD, CL, SRJ, SM and MD are employees of ViiV Healthcare, ML and MG are employees of ViiV Healthcare and shareholders at GlaxoSmithKline. TPD is an employee of GlaxoSmithKline, J-MM reports advisory boards for Gilead, Merck, ViiV Healthcare, Bristol-Myers Squibb (BMS), Janssen and Teva and grants from Gilead, JM-R reports no conflict of interest, JRB reports personal fees from BMS, ViiV Healthcare, Merck Sharpe and Dohme, Gilead, Janssen and Hexal, DAS was an employee of Bristol-Myers Squibb during conduct of the study. JM-R and JL have no conflicts to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

              Author information
              http://orcid.org/0000-0001-6103-8967
              Article
              PONE-D-18-11417
              10.1371/journal.pone.0205368
              6198970
              30352054
              7a17e35c-b191-4f5f-bd45-1c94fd6ad6d0
              © 2018 Morales-Ramirez et al

              This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

              History
              : 8 June 2018
              : 16 September 2018
              Page count
              Figures: 1, Tables: 5, Pages: 15
              Funding
              Funding was provided by Bristol-Myers Squibb, original sponsor (and through the Week 24 analysis) of 205891. ViiV Healthcare UK Limited subsequently acquired the GSK3532795 compound and now supports the study.
              Categories
              Research Article
              Biology and Life Sciences
              Microbiology
              Medical Microbiology
              Microbial Pathogens
              Viral Pathogens
              Immunodeficiency Viruses
              HIV
              HIV-1
              Medicine and Health Sciences
              Pathology and Laboratory Medicine
              Pathogens
              Microbial Pathogens
              Viral Pathogens
              Immunodeficiency Viruses
              HIV
              HIV-1
              Biology and Life Sciences
              Organisms
              Viruses
              Viral Pathogens
              Immunodeficiency Viruses
              HIV
              HIV-1
              Biology and Life Sciences
              Organisms
              Viruses
              Immunodeficiency Viruses
              HIV
              HIV-1
              Biology and life sciences
              Organisms
              Viruses
              RNA viruses
              Retroviruses
              Lentivirus
              HIV
              HIV-1
              Biology and Life Sciences
              Microbiology
              Medical Microbiology
              Microbial Pathogens
              Viral Pathogens
              Retroviruses
              Lentivirus
              HIV
              HIV-1
              Medicine and Health Sciences
              Pathology and Laboratory Medicine
              Pathogens
              Microbial Pathogens
              Viral Pathogens
              Retroviruses
              Lentivirus
              HIV
              HIV-1
              Biology and Life Sciences
              Organisms
              Viruses
              Viral Pathogens
              Retroviruses
              Lentivirus
              HIV
              HIV-1
              Biology and Life Sciences
              Microbiology
              Microbial Control
              Antimicrobial Resistance
              Medicine and Health Sciences
              Pharmacology
              Antimicrobial Resistance
              Medicine and Health Sciences
              Gastroenterology and Hepatology
              Diarrhea
              Medicine and Health Sciences
              Diagnostic Medicine
              Signs and Symptoms
              Diarrhea
              Medicine and Health Sciences
              Pathology and Laboratory Medicine
              Signs and Symptoms
              Diarrhea
              Biology and Life Sciences
              Anatomy
              Body Fluids
              Blood
              Blood Plasma
              Medicine and Health Sciences
              Anatomy
              Body Fluids
              Blood
              Blood Plasma
              Biology and Life Sciences
              Physiology
              Body Fluids
              Blood
              Blood Plasma
              Medicine and Health Sciences
              Physiology
              Body Fluids
              Blood
              Blood Plasma
              Research and Analysis Methods
              Research Design
              Clinical Research Design
              Adverse Events
              Biology and Life Sciences
              Cell Biology
              Cellular Types
              Animal Cells
              Blood Cells
              White Blood Cells
              T Cells
              Biology and Life Sciences
              Cell Biology
              Cellular Types
              Animal Cells
              Immune Cells
              White Blood Cells
              T Cells
              Biology and Life Sciences
              Immunology
              Immune Cells
              White Blood Cells
              T Cells
              Medicine and Health Sciences
              Immunology
              Immune Cells
              White Blood Cells
              T Cells
              Medicine and Health Sciences
              Pharmaceutics
              Dose Prediction Methods
              Adjustment of Dosage at Steady State
              Biology and Life Sciences
              Biochemistry
              Enzymology
              Enzymes
              Transferases
              Aminotransferases
              Biology and Life Sciences
              Biochemistry
              Proteins
              Enzymes
              Transferases
              Aminotransferases
              Custom metadata
              All relevant data are within the paper and its Supporting Information files. GSK3532795 is not available commercially at the moment, but we are open to collaborate with interested researchers on ideas that can improve next generation maturation inhibitors. Restrictions: redacted protocol provided and no confidential patient information can be provided.

              Uncategorized
              Uncategorized

              Comments

              Comment on this article